8-K: NeurAxis Reports Full Year 2023 Results, Restates Prior Financials Due to Accounting Error

NeurAxis, Inc. announced its full year 2023 financial results, which included a restatement of prior financials due to a material accounting error, and highlighted significant growth in insurance coverage and clinical research progress.

Summary

• NeurAxis reported its financial results for the year ended December 31, 2023, with revenue of $2.5 million, a decrease of 8.4% compared to 2022.
• The company experienced a net loss of $14.6 million in 2023, significantly higher than the $4.8 million loss in 2022, primarily due to non-cash charges related to debt conversion upon the IPO and increased general and administrative costs.
• A material accounting error was identified, leading to a restatement of the unaudited financial statements for the three and nine months ended September 30, 2023, which will increase the net loss by $3.7 million and increase additional paid in capital by $3.7 million.
• The company expanded its covered lives to approximately 16 million individuals, a 300% increase from 4 million in April 2023.
• NeurAxis secured $3 million in convertible note financing in November 2023 and an additional $3.1 million in the first quarter of 2024.
• The company anticipates revenue growth in late 2024 and into 2025 due to increased insurance coverage and the commercialization of its rectal expulsion device (RED).

Sentiment

Score: 4

Explanation: The document presents mixed signals. While there are positive developments in insurance coverage and clinical research, the significant net loss, revenue decline, and financial restatement raise concerns. The sentiment is cautiously optimistic but tempered by financial challenges.

Positives

• NeurAxis achieved a 300% increase in covered lives, reaching approximately 16 million individuals.
• The company has secured significant medical policy coverage from major insurance plans.
• Clinical research has shown significant improvements in abdominal pain for patients using IB-Stim.
• The company has a strong pipeline of clinical studies underway for additional indications.
• NeurAxis secured $6.1 million in convertible note financing, strengthening its balance sheet.
• The company is on track to expand medical policy coverage to at least 50 million lives by the end of 2024.
• The company is planning to commercialize the RED device in 2024, which is expected to be a near-term revenue driver.

Negatives

• Revenue decreased by 8.4% in fiscal year 2023 compared to 2022, totaling $2.5 million.
• The company experienced a significant net loss of $14.6 million in 2023, compared to a $4.8 million loss in 2022.
• A material accounting error was identified, requiring a restatement of prior financial statements.
• Cash on hand at December 31, 2023, was only $78.6 thousand.
• The company's net loss was significantly impacted by non-cash charges related to debt conversion upon the IPO.

Risks

• The restatement of financial statements could lead to a loss of investor confidence.
• The company's low cash position could pose a risk to its operations.
• There is a lag between insurance coverage and order placement, which could delay revenue growth.
• The company's future success depends on the commercialization of its products and expansion of insurance coverage.
• The company's ability to achieve its goal of 50 million covered lives by the end of 2024 is not guaranteed.

Future Outlook

The company expects revenue to increase in late 2024 and into 2025 due to expanded insurance coverage and the commercialization of the RED device. They also plan to expand the number of indications for IB-Stim with further clinical studies and FDA submissions over the next three years.

Management Comments

• Brian Carrico, CEO, stated that the publication of strong data will result in strong insurance medical policy coverage, which will drive strong future revenue growth.
• Mr. Carrico believes the company is on track to achieve its goal of having medical policy coverage for at least 50 million lives by the end of 2024.
• Dr. Adrian Miranda, CMO, expressed pride in the depth and breadth of the company's published studies.
• Mr. Carrico anticipates growth in 2024 to be driven by expanding insurance coverage and the commercialization of RED.

Industry Context

The announcement reflects the challenges and opportunities faced by medical technology companies in securing insurance coverage and demonstrating clinical efficacy. The focus on peer-reviewed studies and real-world data is consistent with industry trends towards evidence-based medicine. The expansion of covered lives and the development of new technologies like RED are aimed at addressing unmet needs in the market.

Comparison to Industry Standards

• The 300% increase in covered lives is a significant achievement, suggesting strong market adoption compared to peers in the neuromodulation space.
• The company's gross profit margin of 87.7% is relatively high, indicating a strong pricing strategy and efficient cost management compared to other medical device companies.
• The net loss of $14.6 million is substantial, highlighting the high costs associated with clinical trials, regulatory approvals, and commercialization efforts, which is common in the early stages of medical technology companies.
• The company's focus on publishing peer-reviewed studies is in line with industry best practices for gaining payor coverage and market acceptance, similar to companies like Nevro and Boston Scientific in the neuromodulation field.
• The development of the RED device is a strategic move to expand the company's product portfolio and address a broader market, similar to how companies like Medtronic diversify their offerings.

Stakeholder Impact

• Shareholders will be impacted by the restatement of financial statements and the increased net loss.
• Employees may be affected by the company's financial performance and future growth plans.
• Customers (patients) will benefit from increased insurance coverage and the availability of new technologies.
• Suppliers may be impacted by the company's financial performance and future growth plans.
• Creditors will be impacted by the company's debt financing and financial performance.

Next Steps

• The company plans to file its Annual Report on Form 10-K, including the restated financial statements.
• NeurAxis will continue to expand insurance coverage for its IB-Stim therapy.
• The company will commercialize its rectal expulsion device (RED) in 2024.
• NeurAxis will advance its development pipeline for new indications leveraging its neuromodulation therapy.
• The company will continue to conduct clinical studies and pursue FDA submissions.

Key Dates

Keywords

NeurAxis, IB-Stim, PENFS, neuromodulation, medical technology, insurance coverage, financial results, restatement, rectal expulsion device, RED, pediatric, DGBIs, FAP, IBS